VIDEO: Importance of selecting JAK inhibitors based on individual patient

Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

First to, maybe step back and say, what is the difference between a first and a second generation JAK inhibitor? The big feature being, the first generation are the non-selective JAK inhibitor, such as tofacitinib and baricitinib, where they have non-selectivity about which JAK do they inhibit, JAK 1, 2, 3 or tick two. Versus the second generation, for example, upadacitinib is one where, you know, they're more selective inhibitors of, for example, with upa it's a selective JAK1 inhibitor. So I think really the biggest way I think of them, is the patient in front of me, so if I'm more worried about, you know, adverse effects that I think of more in my mind with the non-selective JAK inhibitors or first generation JAK inhibitors, I tend to lean towards maybe a second generation more. But if it's an otherwise healthy, young person I might be okay positioning first, also with a non-selective JAK inhibitor, given that, you know, of course we've seen more data with them. Like, I know we've had tofacitinib in the market since 2013, so way more data on them at least 2013, at least in the US. I think more depends on the comorbidities of the patient, the patient in front of me in terms of the, which one do I go to first?